Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors
The European Journal of Health Economics · 2025-12 · 26 (9) · 1557-1567
DOI: 10.1007/s10198-025-01786-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift The European Journal of Health Economics, online erschienen am 09.05.2025. Verfasst von Julian Witte und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vandage GmbH, Detmolder Straße 30, 33604, Bielefeld, Germany. Hauptthemen laut MEDLINE: Craniopharyngioma, Pituitary Neoplasms, Obesity, Hypothalamic Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rhythm Pharmaceuticals.
Abstract (Originalsprache)
Background
Rapid and abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or treatment-related damage to the hypothalamus, is called acquired hypothalamic obesity (aHO), and is often linked to craniopharyngioma and/or sellar/suprasellar tumors. Here, we examine the healthcare resource use (HCRU) and costs of aHO following treatment of these tumors.
Methods
We used a retrospective matched cohort design with German statutory health insurance data on 5.42 million people from 2010 to 2021. We applied a novel three-step approach using diagnostic and prescription data to identify patients with treatment- or tumor-related (TTR)-aHO. We measured HCRU and costs across hospitalizations, outpatient visits, visits per specialist group, and outpatient prescription medications.
Results
Compared to non-HO obesity, TTR-aHO is associated with increased hospitalizations, increased outpatient physician visits, and increased prescription use in the two years after incident tumor surgery/radiotherapy. Excess costs of TTR-aHO are €19,900 per patient in the first year and €10,700 in the second, driven by inpatient costs. Cost-intensive hormone replacement therapies like somatropin lead to a sharp increase in prescription costs in the second year.
Conclusions
This study provides the first real-world analysis of TTR-aHO economics, emphasizing the importance of HCRU and costs for decision-making. Previously, economic evaluations have been missing due to the lack of a standard method to identify patients with aHO in retrospective studies. Using a new identification approach, the study reveals that TTR-aHO poses a significant burden in extensive treatment requirements for patients and high related costs for the healthcare system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vandage GmbH, Detmolder Straße 30, 33604, Bielefeld, Germany.
- Rhythm Pharmaceuticals, 222 Berkeley Street, Boston, MA, 02116, USA.
- Vandage GmbH, Detmolder Straße 30, 33604, Bielefeld, Germany. kylie.braegelmann@vandage.de.
- Gene Access GmbH, Seeweg 26, 44263, Dortmund, Germany.
- Department of Pediatrics and Pediatric Hematology/Oncology, University Children's Hospital, Carl von Ossietzky Universität, Klinikum Oldenburg AöR, Rahel-Straus-Straße 10, 26133, Oldenburg, Germany.
Förderung
- Rhythm Pharmaceuticals
Zitieren
APA
Witte, J., Touchot, N., Surmann, B., Braegelmann, K., Flume, M., Beckhaus, J., Friedrich, C., & Müller, H. L. (2025). Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors. The European Journal of Health Economics, 26(9), 1557-1567. https://doi.org/10.1007/s10198-025-01786-3
Vancouver
Witte J, Touchot N, Surmann B, Braegelmann K, Flume M, Beckhaus J, et al. Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors. The European Journal of Health Economics. 2025;26(9):1557-1567. doi:10.1007/s10198-025-01786-3
BibTeX
@article{Witte2025,
author = {Witte, Julian and Touchot, Nicolas and Surmann, Bastian and Braegelmann, Kylie and Flume, Mathias and Beckhaus, Julia and Friedrich, Carsten and Müller, Hermann L},
title = {Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors},
journal = {The European Journal of Health Economics},
year = {2025},
volume = {26},
number = {9},
pages = {1557--1567},
doi = {10.1007/s10198-025-01786-3}
}
EUVIMED